Drug intelligence / Profile preview

EC0225

Development stage: Phase 1
Lead developer: Novartis
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
Administration: Intravenous

Overview

EC0225 is a drug conjugate developed by Endocyte. It consists of folic acid conjugated to desacetylvinblastine hydrazide. The folic acid moiety acts as a targeting agent, binding to folate receptors often overexpressed on the surface of various cancer cells. Desacetylvinblastine hydrazide is a cytotoxic agent, a derivative of vinblastine, which exerts its anticancer effects by inhibiting microtubule formation, thereby disrupting cell division and leading to apoptosis in targeted tumor cells. It is being investigated for the treatment of refractory or metastatic tumors.

Other names: Folic acid desacetylvinblastine hydrazide conjugate

Targets

FOLR1 (FRα)TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on EC0225.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EC0225.

Explore the full profile